Syndax Pharmaceuticals CFO gets 270,000-share options

Available on EDGAR 11/12/2026 - 04:05 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Syndax Pharmaceuticals Inc (SNDX) Chief Financial Officer Aaron Ondrey received a direct stock-option award covering 270,000 common shares on November 9, 2026, with an exercise price of $9.55 per share. The options expire November 9, 2036. Twenty-five percent vests on the one-year anniversary of the vesting commencement date, followed by 1/48 of the shares monthly for 36 months, subject to continued service as an employee, consultant, director or officer. The reported post-transaction share count is 0.

Insider Trade Summary

Grant/Award: 270,000 shares

Grant/Award 1 txn

Insider Ondrey Aaron

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy) F1	270,000	$9.55	$2.58M

Holdings After Transaction: Stock Option (Right to buy) — 0 options (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the total number of shares will vest on the one (1) year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the shares of Common Stock subject to the Option shall vest monthly thereafter during the recipient's continued service as an employee, consultant, director or officer of the Company over the following thirty-six (36) months, until all of the shares subject to the Option are fully vested.

Key Figures

Underlying common shares: 270,000 shares Exercise price: $9.55 per share Option expiration date: November 9, 2036 +3 more

6 metrics

Underlying common shares 270,000 shares Shares covered by the stock-option award granted November 9, 2026

Exercise price $9.55 per share Stock options awarded to Aaron Ondrey

Option expiration date November 9, 2036 Direct stock-option award

Reported shares following transaction 0 shares Post-transaction share count reported for the transaction

Initial vesting tranche 25% Vests on the one-year anniversary of the vesting commencement date

Monthly vesting period 36 months After the initial anniversary vesting

Key Terms

Stock Option (Right to buy), Vesting Commencement Date, fully vested

3 terms

Stock Option (Right to buy) technical

"Stock Option (Right to buy)"

Vesting Commencement Date technical

"one (1) year anniversary of the Vesting Commencement Date"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

fully vested technical

"until all of the shares subject to the Option are fully vested"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SNDX shares are covered by Aaron Ondrey's stock-option award?

The award covers 270,000 common shares and has an exercise price of $9.55 per share.

What are the vesting terms for Aaron Ondrey's SNDX stock options?

Twenty-five percent vests on the one-year anniversary of the vesting commencement date, followed by 1/48 of the shares monthly for 36 months, subject to continued service as an employee, consultant, director or officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ondrey Aaron

(Last) (First) (Middle)

730 THIRD AVENUE

FLOOR 9

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Syndax Pharmaceuticals Inc [ SNDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$9.55	11/09/2026		A		270,000		(1)	11/09/2036	Common Stock	270,000	$9.55	0	D

Explanation of Responses:

1. Twenty-five percent (25%) of the total number of shares will vest on the one (1) year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the shares of Common Stock subject to the Option shall vest monthly thereafter during the recipient's continued service as an employee, consultant, director or officer of the Company over the following thirty-six (36) months, until all of the shares subject to the Option are fully vested.

	/s/ Michael A. Metzger, Attorney-in-Fact	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)